Francesco Blasi

Dr. Francesco Blasi

Università degli studi di Milano
+1
orcid

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2017 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
Eva PolverinoEva Polverino
Eva Polverino
PGPieter C. Goeminne
Pieter C. Goeminne
MMMelissa J. McDonnell
Melissa J. McDonnell
SAStefano Aliberti
Stefano Aliberti
SMSara E. Marshall
Sara E. Marshall
JCJames D. Chalmers
James D. Chalmers
Bronchiectasis in adults is a chronic disorder associated with poor quality of life and frequent exacerbations in many patients. There have been no previous international guidelines.The European Respiratory Society guidelines for the management of adult bronchiectasis describe the appropriate investigation and treatment strategies determined by a systematic review of the literature.A multidisciplinary group representing respiratory medicine, microbiology, physiotherapy, thoracic surgery, primary care, methodology and patients considered the most relevant clinical questions (for both clinicians and patients) related to management of bronchiectasis. Nine key clinical questions were generated and a systematic review was conducted to identify published systematic reviews, randomised clinical trials and observational studies that answered these questions. We used the GRADE approach to define the quality of the evidence and the level of recommendations. The resulting guideline addresses the investigation of underlying causes of bronchiectasis, treatment of exacerbations, pathogen eradication, long term antibiotic treatment, anti-inflammatories, mucoactive drugs, bronchodilators, surgical treatment and respiratory physiotherapy.These recommendations can be used to benchmark quality of care for people with bronchiectasis across Europe and to improve outcomes.

1 February 2005 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
Marco ConfalonieriMarco Confalonieri
Marco Confalonieri
RURosario Urbino
Rosario Urbino
APAlfredo Potena
Alfredo Potena
MPMarco Piattella
Marco Piattella
PPPiercarlo Parigi
Piercarlo Parigi
GMG. Umberto Meduri
G. Umberto Meduri
We hypothesize that hydrocortisone infusion in severe community-acquired pneumonia attenuates systemic inflammation and leads to earlier resolution of pneumonia and a reduction in sepsis-related complications. In a multicenter trial, patients admitted to the Intensive Care Unit (ICU) with severe community-acquired pneumonia received protocol-guided antibiotic treatment and were randomly assigned to hydrocortisone infusion or placebo. Hydrocortisone was given as an intravenous 200-mg bolus followed by infusion at a rate of 10 mg/hour for 7 days. Primary end-points of the study were improvement in PaO2:FIO2 (PaO2:FIO2 > 300 or ⩾ 100 increase from study entry) and multiple organ dysfunction syndrome (MODS) score by Study Day 8 and reduction in delayed septic shock. Forty-six patients entered the study. At study entry, the hydrocortisone group had lower PaO2:FIO2, and higher chest radiograph score and C-reactive protein level. By Study Day 8, treated patients had, compared with control subjects, a significant improvement in PaO2:FIO2 (p = 0.002) and chest radiograph score (p < 0.0001), and a significant reduction in C-reactive protein levels (p = 0.01), MODS score (p = 0.003), and delayed septic shock (p = 0.001). Hydrocortisone treatment was associated with a significant reduction in length of hospital stay (p = 0.03) and mortality (p = 0.009).

18 March 2015 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
KLKnut Lönnroth
Knut Lönnroth
GMGiovanni Battista Migliori
Giovanni Battista Migliori
IAIbrahim Abubakar
Ibrahim Abubakar
LDLia D'Ambrosio
Lia D'Ambrosio
GVGerard de Vries
Gerard de Vries
MRMario C. Raviglione
Mario C. Raviglione
This paper describes an action framework for countries with low tuberculosis (TB) incidence (<100 TB cases per million population) that are striving for TB elimination. The framework sets out priority interventions required for these countries to progress first towards “pre-elimination” (<10 cases per million) and eventually the elimination of TB as a public health problem (less than one case per million). TB epidemiology in most low-incidence countries is characterised by a low rate of transmission in the general population, occasional outbreaks, a majority of TB cases generated from progression of latent TB infection (LTBI) rather than local transmission, concentration to certain vulnerable and hard-to-reach risk groups, and challenges posed by cross-border migration. Common health system challenges are that political commitment, funding, clinical expertise and general awareness of TB diminishes as TB incidence falls. The framework presents a tailored response to these challenges, grouped into eight priority action areas: 1) ensure political commitment, funding and stewardship for planning and essential services; 2) address the most vulnerable and hard-to-reach groups; 3) address special needs of migrants and cross-border issues; 4) undertake screening for active TB and LTBI in TB contacts and selected high-risk groups, and provide appropriate treatment; 5) optimise the prevention and care of drug-resistant TB; 6) ensure continued surveillance, programme monitoring and evaluation and case-based data management; 7) invest in research and new tools; and 8) support global TB prevention, care and control. The overall approach needs to be multisectorial, focusing on equitable access to high-quality diagnosis and care, and on addressing the social determinants of TB. Because of increasing globalisation and population mobility, the response needs to have both national and global dimensions.

15 October 2013 in Thorax
Verified
Journal Article
Open access
PDF file
Antoni TorresAntoni Torres
Antoni Torres
WPWilly E Peetermans
Willy E Peetermans
GVGiovanni Viegi
Giovanni Viegi
Francesco BlasiFrancesco Blasi
Francesco Blasi
Background Community-acquired pneumonia (CAP) causes considerable morbidity and mortality in adults, particularly in the elderly. Methods Structured searches of PubMed were conducted to identify up-to-date information on the incidence of CAP in adults in Europe, as well as data on lifestyle and medical risk factors for CAP. Results The overall annual incidence of CAP in adults ranged between 1.07 to 1.2 per 1000 person-years and 1.54 to 1.7 per 1000 population and increased with age (14 per 1000 person-years in adults aged ≥65 years). Incidence was also higher in men than in women and in patients with chronic respiratory disease or HIV infection. Lifestyle factors associated with an increased risk of CAP included smoking, alcohol abuse, being underweight, having regular contact with children and poor dental hygiene. The presence of comorbid conditions, including chronic respiratory and cardiovascular diseases, cerebrovascular disease, Parkinson's disease, epilepsy, dementia, dysphagia, HIV or chronic renal or liver disease all increased the risk of CAP by twofold to fourfold. Conclusion A range of lifestyle factors and underlying medical conditions are associated with an increased risk of CAP in European adults. Understanding of the types of individual at greatest risk of CAP can help to ensure that interventions to reduce the risk of infection and burden of disease are targeted appropriately.

1 December 2005 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
MWM. Woodhead
M. Woodhead
Francesco BlasiFrancesco Blasi
Francesco Blasi
SES. Ewig
S. Ewig
GHG. Huchon
G. Huchon
MLM. Leven
M. Leven
TVT. J. M. Verheij
T. J. M. Verheij
Since the 1998 European Respiratory Society (ERS) lower respiratory tract infection (LRTI) guidelines 1 were published, the evidence on which they were based has increased and the methods for guideline development have been refined. Against this background, these new guidelines have been developed.

8 June 2017 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
AHAdam T. Hill
Adam T. Hill
CHCharles S. Haworth
Charles S. Haworth
SAStefano Aliberti
Stefano Aliberti
ABAlan Barker
Alan Barker
Francesco BlasiFrancesco Blasi
Francesco Blasi
TATimothy Aksamit
Timothy Aksamit
There is a need for a clear definition of exacerbations used in clinical trials in patients with bronchiectasis. An expert conference was convened to develop a consensus definition of an exacerbation for use in clinical research.A systematic review of exacerbation definitions used in clinical trials from January 2000 until December 2015 and involving adults with bronchiectasis was conducted. A Delphi process followed by a round-table meeting involving bronchiectasis experts was organised to reach a consensus definition. These experts came from Europe (representing the European Multicentre Bronchiectasis Research Collaboration), North America (representing the US Bronchiectasis Research Registry/COPD Foundation), Australasia and South Africa.The definition was unanimously approved by the working group as: a person with bronchiectasis with a deterioration in three or more of the following key symptoms for at least 48 h: cough; sputum volume and/or consistency; sputum purulence; breathlessness and/or exercise tolerance; fatigue and/or malaise; haemoptysis AND a clinician determines that a change in bronchiectasis treatment is required.The working group proposes the use of this consensus-based definition for bronchiectasis exacerbation in future clinical research involving adults with bronchiectasis.